Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
by eazee-designstudio
Data from a randomized, multi-center, 170 patient Phase II study with resminostat as first-line treatment of advanced liver cancer presented at 2017 Gastrointestinal Cancers Symposium shows substantial increase in overall survival
